Saturday, May 20
|
7:15 a.m. |
Continental Breakfast – Posters Available |
8 a.m. |
Welcome from the ATS President
- Gregory P. Downey, MD, ATSF - National Jewish Health
|
8:10 a.m. |
Co-Chair Address: State of Innovation and Investment
- Cecilia Gonzalo, MBA – Partner, Oberland Capital
- Tim Watkins, MD, MS – Vice President, Clinical Development; Head – Fibrosis & Pulmonary Diseases - Inflammation Therapeutics, Gilead Sciences
|
8:30 a.m. |
Showcase One: Asthma, COPD, and Airway Inflammation Innovators
- Moderator: Ted Reiss, MD, MBE, ATSF
- Avalo Therapeutics, Inc.
- Kinaset Therapeutics
- RAGE Biotech Pty Ltd
- ReAlta Life Sciences
- SpliSense
|
9 a.m. |
Panel Discussion: Venture Capital
- Moderator: Jamil Beg – Partner, 5AM Ventures
- Tiba Aynechi, PhD – General Partner, Norwest Venture Partners
- Christine Borowski, PhD – Vice President, Access Industries
- Cristina Ghenoiu, PhD – Principal, RA Capital
- Bert Kinsey, PhD, PharmD - Research Analyst, Principal - Eventide Asset Management
- Maneka Mirchandaney – Principal, Viking Global Investors
- Samantha Palmer, PhD, MBA - Executive Director, Business Development, Amgen Ventures
|
9:45 a.m. |
Networking Break – Posters Available |
10:15 a.m. |
Showcase Two: Critical Care, Chronic Cough and Sleep Innovators
- Moderator: Courtney Crim, MD, ATSF
- Apnimed
- Atelerix Life Sciences
- KeViRx, Inc.
- Trevi Therapeutics
- Xequel Bio, Inc.
|
10:45 a.m. |
Fireside with the FDA: How Do We Accelerate Respiratory Discovery?
- Moderator: Robert J. Meyer, MD – Principal, Greenleaf Health
- Sally Seymour, MD – Office of Immunology and Inflammation - Division of Pulmonology, Allergy, and Critical Care (DPACC); US Food and Drug Administration
- Mary Tran Than Hai, MD - Deputy Director for Clinical, Office of New Drugs; U.S. Food and Drug Administration
- Onyeka Illoh, OD, MPH - Team Leader, Team Leader, Division of Clinical Outcome Assessment U.S. Food and Drug Administration
|
11:30 a.m. |
Showcase Three: : Technology Innovators: Devices, Digital, AI and More
- Moderator: Jason Kirkness, PhD, ATSF
- FluidIQ
- ImmuneIQ
- Samay
- Spiro Medical
- VIDA
|
12 p.m. |
Lunch and Networking– Posters Available |
1 p.m. |
RIS Success Story Presentation - By Invitation
- Peter M. Small, MD – Chief Medical Officer, Hyfe, Inc.
|
1:15 p.m. |
Panel: Business Development
- Moderator: Amanda Mason, PhD – Director, Business Development, Amgen
- Jane Escott, PhD – Director, Respiratory Search and Evaluation Leader, AstraZeneca
- Silke Hobbie, PhD – Global Head of Business Development & Licensing – Respiratory, Boehringer Ingelheim
- Christopher Mortko, PhD, MBA - Vice President, Head Search and Evaluation, Business Development & Licensing, Merck
- Eugene J. Sullivan, MD, FCCP – Chief Product Strategy Officer, Insmed
- Jeannie Rojas, PhD, MBA – Senior Director, Worldwide Business Development - GlaxoSmithKline
- Aryeh Fischer, MD - Clinical Development Lead, Lung Fibrosis, Bristol Myers Squibb
|
2 p.m. |
Showcase Four: Inflammation, Infectious Disease and Other Innovators
- Moderator: David Morris, MD
- Aerami Therapeutics
- Arrowhead Pharmaceuticals
- AuraVax Therapeutics, Inc.
- Rnatics
- Synairgen
|
2:30 p.m. |
Networking Break - Posters Available |
3 p.m. |
Panel: Biomarkers and Innovation
- Moderator: Tim Watkins, MD, MS - Vice President, Clinical Development; Head – Fibrosis & Pulmonary Diseases - Inflammation Therapeutics, Gilead Sciences
- Bastiaan Driehuys, PhD –Chief Scientific Officer, Polarean Imaging
- Jonathan G. Goldin, MD – Section Chief and Head of Radiology, UCLA Medical Center
- Sydney B. Montesi, MD – Massachusetts General Hospital
- Dave Morris, MD – President, Technologies and Therapeutics, Valo Health
- John Sundy, MD, PhD – Chief Medical Officer and Head of Research and Development, Seismic Therapeutic
|
3:45 p.m. |
Showcase Five: Fibrosis Innovators
- Moderator: Mary Strek, MD
- Atyr Pharma
- Avalyn Pharmaceuticals
- Lassen Therapeutics
- Pieris Pharmaceuticals
- Prosia
- Vicore Pharma
|
4:15 p.m. |
Closing Remarks and Sponsor Recognition
- Cecilia Gonzalo, MBA – Partner, Oberland Capital
- Tim Watkins, MD, MS - Vice President, Clinical Development; Head – Fibrosis & Pulmonary Diseases - Inflammation Therapeutics, Gilead Sciences
|
4:30 p.m. |
Networking Reception – Posters Available |
6 p.m. |
Adjourn |